Tyl J W, Blank L E, Koornneef L
Orbital Center, Amsterdam, The Netherlands.
Ophthalmology. 1997 Sep;104(9):1475-9. doi: 10.1016/s0161-6420(97)30113-4.
To evaluate whether the use of iridium-192 brachytherapy would reduce the incidence of complications noted with external beam radiation therapy in patients with orbital tumors.
This study is a retrospective review of a clinical series of 25 patients with various orbital tumors treated with brachytherapy between 1988 and 1995.
Patients were observed for an average of 40 months (range, 16-88 months) during which one patient died of metastatic disease and 24 patients are alive with no evidence of disease. Recurrent disease was observed in four patients. In 3 patients, exenteration was necessary and in 22 patients, the eye was preserved. The visual acuities after therapy ranged from no light perception to 20/20 (average, 20/40).
Since brachytherapy has been used as an alternative to exenteration, the results of this treatment have been excellent in most patients. However, in advanced disease, external radiation therapy or even mutilating surgery still remains inevitable.
评估使用铱-192近距离放射疗法是否会降低眼眶肿瘤患者接受外照射放疗时出现并发症的发生率。
本研究是对1988年至1995年间接受近距离放射疗法治疗的25例不同眼眶肿瘤患者的临床系列进行的回顾性研究。
患者平均观察期为40个月（范围16 - 88个月），期间1例患者死于转移性疾病，24例患者存活且无疾病证据。4例患者出现疾病复发。3例患者需要进行眼眶内容剜除术，22例患者的眼球得以保留。治疗后的视力范围从无光感到20/20（平均为20/40）。
由于近距离放射疗法已被用作眼眶内容剜除术的替代方法，该治疗方法在大多数患者中效果良好。然而，对于晚期疾病，外照射放疗甚至致残性手术仍然不可避免。
